Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genexine, Inc.

http://www.genexine.com

Latest From Genexine, Inc.

Asia Deal Watch: ProGen To Partner With Rani On GLP-2 Agonist In Obesity

Plus deals involving Healios/Astellas Institute for Regenerative Medicine, Otsuka/Ionis, IMBiologics/Navigator and more.

Deal Watch Business Strategies

Ajinomoto Builds Gene Therapy CDMO Capabilities Through $554m Forge Acquisition

With an ambitious growth plan for its CDMO operations, Ajinomoto is planning to complete the acquisition of Forge Biologics Holdings by December, adding the US-based firm’s capabilities in gene therapy services.

Commercial Deals

Korea Kick-Starts Major Consortium For Next-Gen mRNA Vaccines

South Korea is stepping on the gas to develop its own mRNA COVID-19 vaccine and eventually next generation mRNA platform technology for use in other diseases, to meet its goal of becoming a global vaccine hub.

South Korea Coronavirus COVID-19

Coronavirus Update: Inovio Looks Outside US To Continue Vaccine Development

Inovio looks to countries outside the US to continue late-stage development of its vaccine, while a South Korean firm strikes a supply deal with Indonesia and Japan approves a new drug for COVID-19. 

Coronavirus COVID-19 BioPharmaceutical
See All

Company Information

UsernamePublicRestriction

Register